494 related articles for article (PubMed ID: 22027398)
1. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
Lidegaard Ø; Nielsen LH; Skovlund CW; Skjeldestad FE; Løkkegaard E
BMJ; 2011 Oct; 343():d6423. PubMed ID: 22027398
[TBL] [Abstract][Full Text] [Related]
2. Hormonal contraception and risk of venous thromboembolism: national follow-up study.
Lidegaard Ø; Løkkegaard E; Svendsen AL; Agger C
BMJ; 2009 Aug; 339():b2890. PubMed ID: 19679613
[TBL] [Abstract][Full Text] [Related]
3. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
4. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
5. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
6. Combined oral contraceptives: venous thrombosis.
de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
[TBL] [Abstract][Full Text] [Related]
7. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
Farmer RD; Lawrenson RA
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
[TBL] [Abstract][Full Text] [Related]
8. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
Jick SS; Hernandez RK
BMJ; 2011 Apr; 342():d2151. PubMed ID: 21511805
[TBL] [Abstract][Full Text] [Related]
9. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
Lidegaard O; Nielsen LH; Skovlund CW; Løkkegaard E
BMJ; 2012 May; 344():e2990. PubMed ID: 22577198
[TBL] [Abstract][Full Text] [Related]
10. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
Parkin L; Sharples K; Hernandez RK; Jick SS
BMJ; 2011 Apr; 342():d2139. PubMed ID: 21511804
[TBL] [Abstract][Full Text] [Related]
11. Smoking and use of oral contraceptives: impact on thrombotic diseases.
Lidegaard O
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies.
Shapiro S; Dinger J
J Fam Plann Reprod Health Care; 2010 Jan; 36(1):33-8. PubMed ID: 20067670
[TBL] [Abstract][Full Text] [Related]
13. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
14. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
Plu-Bureau G; Sabbagh E; Hugon-Rodin J
Gynecol Obstet Fertil Senol; 2018 Dec; 46(12):823-833. PubMed ID: 30389542
[TBL] [Abstract][Full Text] [Related]
15. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
Lidegaard O
Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
Carr BR; Ory H
Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
[TBL] [Abstract][Full Text] [Related]
17. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
[TBL] [Abstract][Full Text] [Related]
18. Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.
Salem JE; Dureau P; Bachelot A; Germain M; Voiriot P; Lebourgeois B; Trégouët DA; Hulot JS; Funck-Brentano C
JAMA Cardiol; 2018 Sep; 3(9):877-882. PubMed ID: 30073300
[TBL] [Abstract][Full Text] [Related]
19. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.
Heinemann K; Heinemann LA
J Fam Plann Reprod Health Care; 2011 Jul; 37(3):132-5. PubMed ID: 21659330
[No Abstract] [Full Text] [Related]
20. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.
Jick H; Kaye JA; Vasilakis-Scaramozza C; Jick SS
BMJ; 2000 Nov; 321(7270):1190-5. PubMed ID: 11073511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
